Want to join the conversation?
Biotechnology company $UTHR said it has announced receipt of a Paragraph IV Certification Notice Letter on Feb. 18, 2016 from Actavis advising that Actavis has submitted an ANDA to the U.S. Food and Drug Administration (FDA) requesting approval to market a generic version of the 2.5 mg strength of Orenitram (treprostinil) Extended-Release Tablets.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?